Biomarker partner to support planned Phase II

Herantis Pharma has announced a strategic collaboration with Indivi (a Basel-based techbio company focused on advancing precision medicine in neuroscience drug development) to support its Phase II plans for lead asset, HER-096, in Parkinson’s disease (PD). Under the partnership, Herantis intends to use Indivi’s digital biomarker platform to enable the detection of early treatment effects in the study, alongside conventional clinical assessments. We view this as a positive development for Herantis’s lead programme, offering the opportunity to build upon encouraging biomarker outcomes in the prior Phase Ib trial. According to this latest announcement, preparations for the Phase II proof-of-concept trial are on track, with management now op...